Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02723604 · ClinicalTrials.gov registry record · NA
Low-Level Laser Therapy for Prevention of Oral Mucositis
A NA study of Mucositis, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02723604 is a NA study of Mucositis that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 25 participants, below the 55-participant average among 4 other Mucositis trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02723604, a NA study of Mucositis, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to examine the efficacy of prophylactic low-level laser therapy (LLLT) to reduce the incidence of oral mucositis and adverse events in patients receiving combined modality therapy consisting of chemotherapy and radiation therapy for head and neck cancer.
Conditions Studied
Interventions
- DEVICE Low Level Laser Therapy
Study Locations (1)
Michigan
- Wayne State University/Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-03 |
| Est. Completion | 2021-09-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02723604
The ClinicalTrials.gov registry entry for NCT02723604 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55-participant average among 4 other Mucositis trials with a reported enrollment target (55% lower). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mucositis appearing as the primary indexed condition, and to 1 intervention - of which Low Level Laser Therapy is the first listed.
NCT02723604 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02723604 about?
NCT02723604 is a clinical study titled "Low-Level Laser Therapy for Prevention of Oral Mucositis". The overall purpose of this study is to examine the efficacy of prophylactic low-level laser therapy (LLLT) to reduce the incidence of oral mucositis and adverse events in patients receiving combined modality therapy consisting of chemotherapy and radiation therapy for head and neck cancer.
What is the current status of trial NCT02723604?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2016-03. Estimated completion is 2021-09-13.
What conditions does trial NCT02723604 study?
This clinical trial studies the following conditions: Mucositis.
What interventions are being tested in trial NCT02723604?
The interventions under investigation include: Low Level Laser Therapy (DEVICE).
Who is sponsoring clinical trial NCT02723604?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02723604 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness
RECRUITING · NA
-
Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment
COMPLETED · NA
-
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
RECRUITING · Phase 2
-
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.